| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma |
|
Medicine details |
|
| Medicine name | vemurafenib (Zelboraf®) |
| Formulation | 240 mg film-coated tablet |
| Reference number | 1391 |
| Indication | Monotherapy for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/02/2012 |
| NICE guidance | |